IGF1RES
MCID: INS024
MIFTS: 75

Insulin-Like Growth Factor I (IGF1RES) malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Neuronal diseases, Ear diseases, Mental diseases

Aliases & Classifications for Insulin-Like Growth Factor I

Aliases & Descriptions for Insulin-Like Growth Factor I:

Name: Insulin-Like Growth Factor I 54
Insulin-Like Growth Factor I, Resistance to 54 24 13 69
Insulin-Like Growth Factor I Deficiency 54 50 24 69
Resistance to Insulin-Like Growth Factor I 66 29
End-Organ Insensitivity to Somatomedin 24 66
Igf-I Resistance 24 52
Igf1 Deficiency 50 24
Growth Retardation with Sensorineural Deafness and Mental Retardation 50
Growth Delay Due to Insulin-Like Growth Factor I Resistance 56
Insulin-Like Growth Factor 1 Resistance to 50
Resistance to Insulin-Like Growth Factor 1 24
Insulin-Like Growth Factor 1 Deficiency 24
Insulin-Like Growth Factor 1 Resistance 66
Somatomedin End-Organ Insensitivity to 50
Somatomedin-C Resistance to 50
Resistance to Somatomedin-C 66
Resistance to Igf-1 56
Igf-1 Resistance 50
Igfi Resistance 24
Igf1 Resistance 66
Igf1res 66

Characteristics:

Orphanet epidemiological data:

56
growth delay due to insulin-like growth factor i resistance
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal;

HPO:

32
insulin-like growth factor i:
Inheritance autosomal recessive inheritance autosomal dominant inheritance
Onset and clinical course congenital onset


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

Orphanet 56 ORPHA73273
ICD10 via Orphanet 34 E34.3
MeSH 42 D006130

Summaries for Insulin-Like Growth Factor I

UniProtKB/Swiss-Prot : 66 Insulin-like growth factor 1 resistance: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels.

MalaCards based summary : Insulin-Like Growth Factor I, also known as insulin-like growth factor i, resistance to, is related to primary biliary cirrhosis and growth retardation with deafness and mental retardation due to igf1 deficiency, and has symptoms including pectus excavatum, clinodactyly and intellectual disability. An important gene associated with Insulin-Like Growth Factor I is IGF1R (Insulin Like Growth Factor 1 Receptor), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include breast, prostate and bone, and related phenotypes are Decreased viability and growth/size/body region

Description from OMIM: 270450 608747

Related Diseases for Insulin-Like Growth Factor I

Diseases related to Insulin-Like Growth Factor I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 284)
id Related Disease Score Top Affiliating Genes
1 primary biliary cirrhosis 30.0 IGF1 IGFBP1 INS INSR IRS1
2 growth retardation with deafness and mental retardation due to igf1 deficiency 11.9
3 laron dwarfism 11.6
4 acid-labile subunit, deficiency of 11.1
5 breast cancer 10.8
6 prostatitis 10.7
7 prostate cancer 10.6
8 acromegaly 10.6
9 growth hormone deficiency 10.6
10 obesity 10.5
11 endotheliitis 10.5
12 pancreatitis 10.5
13 neuronitis 10.4
14 hepatitis 10.4
15 neuroblastoma 10.4
16 colorectal cancer 10.4
17 thyroiditis 10.4
18 seow najjar syndrome 10.4 IGF1 IGFBP3 INS
19 spondylometaphyseal dysplasia, megarbane-dagher-melike type 10.4 GH1 IGF1 IGFBP3
20 brain angioma 10.4 IGF1 IRS1
21 intellectual disability-developmental delay-contractures syndrome 10.4 INS INSR
22 femur bifid with monodactylous ectrodactyly 10.4 IGF1 IGF2 INSR
23 microvascular complications of diabetes 3 10.3 GH1 GHR IGF1
24 congenital articular rigidity 10.3 IGF2 IGFBP2 IGFBP3
25 sohval soffer syndrome 10.3 IGF1 IGFBP3
26 leg dermatosis 10.3 IGF1R INS INSR
27 deafness, autosomal recessive 74 10.3 EGF IGF1 IGF2
28 ossification of the posterior longitudinal ligament of spine 10.3 GH1 GHR IGF1
29 brucella canis brucellosis 10.3 IGF1 IGF2 INS
30 lung cancer 10.3
31 pancreatic cancer 10.3
32 gerstmann syndrome 10.3 IGF1 IGF2 IGFBP3 INS
33 microtia, hearing impairment, and cleft palate 10.3 GH1 GHR IGF1 IGFBP3
34 dykes markes harper syndrome 10.3 GH1 GHR IGF1
35 pelvic muscle wasting 10.3 IGF1 IGFBP1 INS INSR
36 cervix squamous papilloma 10.3 GH1 IGF1 IGFBP3 INS
37 coronary aneurysm 10.3 GHR IGF1R IGFBP2 IGFBP3
38 argininosuccinic aciduria 10.3 IGF1 IGF2 IGFBP1 IGFBP3
39 gynandroblastoma 10.3 GH1 GHR IGF1 IGFBP3
40 ovarian cancer 10.3
41 capillary lymphangioma 10.3 GH1 GHR IGF1 INS
42 neurogenic arthropathy 10.3 IGF1 IGF2 INS IRS1
43 tinea unguium 10.3 IGFBP1 IGFBP4 IGFBP5
44 polycystic ovary syndrome 10.3
45 osteoporosis 10.3
46 diarrhea 3, secretory sodium, congenital, syndromic 10.3 IGF1 IGF1R IGFBP3 INS INSR
47 urethra clear cell adenocarcinoma 10.3 GH1 IGF1 INS
48 diabetic cataract 10.3 IGF2 INS INSR
49 haverhill fever 10.3 EGF IGF1 IGF2
50 mucopolysaccharidosis type vi 10.3 GH1 GHR IGF1

Graphical network of the top 20 diseases related to Insulin-Like Growth Factor I:



Diseases related to Insulin-Like Growth Factor I

Symptoms & Phenotypes for Insulin-Like Growth Factor I

Symptoms by clinical synopsis from OMIM:

270450

Clinical features from OMIM:

270450 608747

Human phenotypes related to Insulin-Like Growth Factor I:

56 32 (show all 26)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pectus excavatum 56 32 Frequent (79-30%) HP:0000767
2 clinodactyly 56 32 Frequent (79-30%) HP:0030084
3 intellectual disability 56 32 Frequent (79-30%) HP:0001249
4 delayed skeletal maturation 56 32 Very frequent (99-80%) HP:0002750
5 wide nasal bridge 56 32 Frequent (79-30%) HP:0000431
6 microcephaly 56 32 Frequent (79-30%) HP:0000252
7 smooth philtrum 56 32 Frequent (79-30%) HP:0000319
8 short stature 56 32 Very frequent (99-80%) HP:0004322
9 short palm 56 32 Frequent (79-30%) HP:0004279
10 everted lower lip vermilion 56 32 Frequent (79-30%) HP:0000232
11 wide intermamillary distance 56 32 Frequent (79-30%) HP:0006610
12 intrauterine growth retardation 56 32 Very frequent (99-80%) HP:0001511
13 broad nasal tip 56 32 Frequent (79-30%) HP:0000455
14 thin vermilion border 56 32 Frequent (79-30%) HP:0000233
15 motor delay 56 32 Frequent (79-30%) HP:0001270
16 agitation 32 HP:0000713
17 delayed speech and language development 32 HP:0000750
18 abnormal facial shape 32 HP:0001999
19 long philtrum 32 HP:0000343
20 anxiety 32 HP:0000739
21 growth delay 56 Very frequent (99-80%)
22 thin upper lip vermilion 32 HP:0000219
23 decreased body weight 32 HP:0004325
24 radial deviation of finger 32 HP:0009466
25 abnormality of the rib cage 32 HP:0001547
26 increased serum insulin-like growth factor 1 {comment="hpo 32 HP:0030269

UMLS symptoms related to Insulin-Like Growth Factor I:


agitation

GenomeRNAi Phenotypes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.5 ITGB3
2 Decreased viability GR00221-A-1 10.5 IGF1R INSR IRS1 AKT1 AKT2
3 Decreased viability GR00221-A-2 10.5 AKT1 IGF1R INSR IRS1 ITGAV ITGB3
4 Decreased viability GR00221-A-3 10.5 AKT1 IGF1R INSR AKT2
5 Decreased viability GR00221-A-4 10.5 INSR ITGB3 AKT1 AKT2
6 Decreased viability GR00301-A 10.5 IGF1R AKT2
7 Decreased viability GR00342-S-2 10.5 IGF1R IRS1
8 Decreased viability GR00342-S-3 10.5 IRS1 AKT2
9 Decreased viability GR00381-A-1 10.5 ITGAV
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.19 GH1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.19 INSR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.19 IGF1R
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.19 IGF1R
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.19 GH1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.19 INSR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.19 INSR AKT1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.19 AKT2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.19 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.19 IGF1R INSR AKT1 AKT2 GH1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.19 INSR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.19 IGF1R
22 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 AKT2 IGF1R IRS1 ITGA6 ITGAV ITGB3
23 Increased cell death HMECs cells GR00103-A-0 9.5 IGF1R IGFBP4 IGFBP6 INS INSR IRS1
24 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 AKT2 IGF1R INSR

MGI Mouse Phenotypes related to Insulin-Like Growth Factor I:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 IGF1R IGF2 IGFBP3 IGFBP4 IGFBP5 INS
2 endocrine/exocrine gland MP:0005379 10.41 AKT2 EGF GHR IGF1 IGF1R IGF2
3 cellular MP:0005384 10.38 AKT2 GHR IGF1 IGF1R IGF2 IGFBP1
4 cardiovascular system MP:0005385 10.35 INS INSR IRS1 ITGA6 ITGAV ITGB3
5 immune system MP:0005387 10.35 AKT1 AKT2 EGF GHR IGF1 IGF1R
6 homeostasis/metabolism MP:0005376 10.34 AKT1 AKT2 GHR IGF1 IGF1R IGF2
7 adipose tissue MP:0005375 10.32 IGF1 IGF1R IGFBP3 IGFBP4 IGFBP5 INS
8 hematopoietic system MP:0005397 10.32 AKT1 AKT2 GHR IGF1 IGF1R IGF2
9 muscle MP:0005369 10.25 AKT1 AKT2 GHR IGF1 IGF1R IGF2
10 liver/biliary system MP:0005370 10.21 AKT1 AKT2 GHR IGF1R IGF2 IGFBP1
11 integument MP:0010771 10.2 AKT1 AKT2 EGF GHR IGF1 IGF1R
12 digestive/alimentary MP:0005381 10.16 EGF IGF1R IGF2 INS INSR ITGA6
13 embryo MP:0005380 10.15 ITGA6 ITGAV ITGB3 AKT1 GHR IGF1R
14 nervous system MP:0003631 10.06 AKT1 AKT2 GHR IGF1 IGF1R IGF2
15 neoplasm MP:0002006 9.91 ITGA6 ITGAV ITGB3 AKT1 AKT2 IGF1
16 renal/urinary system MP:0005367 9.91 GHR IGF1 IGF2 IGFBP2 INS INSR
17 reproductive system MP:0005389 9.85 EGF GHR IGF1 IGF1R IGF2 INS
18 respiratory system MP:0005388 9.56 IGF1R IGF2 INSR ITGA6 ITGB3 AKT1
19 skeleton MP:0005390 9.28 AKT1 AKT2 GHR IGF1 IGF1R IGF2

Drugs & Therapeutics for Insulin-Like Growth Factor I

Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757 53477783
3
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
4
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
5
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Tibolone Approved Phase 4 5630-53-5
8
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
9
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Insulin Aspart Approved Phase 4 116094-23-6 16132418
11
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Fosinopril Approved Phase 4 98048-97-6 55891
14
Sodium oxybate Approved Phase 4 502-85-2 5360545
15
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
18
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
19
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
20
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
21
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
22
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
23
Desogestrel Approved Phase 4 54024-22-5 40973
24
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
25
Norelgestromin Approved Phase 4 53016-31-2 13752005
26
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
27
Liraglutide Approved Phase 4 204656-20-2
28
Verapamil Approved Phase 4 52-53-9 2520
29
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
30
Dehydroepiandrosterone Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 53-43-0 9860744
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Imatinib Mesylate Phase 4 123596
35 Complement Factor I Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 insulin Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Insulin, Globin Zinc Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Adrenergic Agents Phase 4,Phase 2,Phase 3
40 Adrenergic Agonists Phase 4,Phase 2,Phase 3
41 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3
42 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
43 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
44 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3,Phase 1
48 Estradiol 3-benzoate Phase 4,Phase 2,Phase 3,Phase 1
49 Estradiol valerate Phase 4,Phase 2,Phase 3,Phase 1 979-32-8
50 Estrogens Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 708)
id Name Status NCT ID Phase
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
2 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
3 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4
4 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4
5 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
6 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4
8 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD. Completed NCT02092584 Phase 4
9 Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study) Completed NCT00710307 Phase 4
10 IGF1 Generation Test Completed NCT00145457 Phase 4
11 The Effect of Ophiocephalus Striatus Extract on Levels of IGF-1, Albumin, and MNA Score in Elderly With Malnutrition Completed NCT03065595 Phase 4
12 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4
13 Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat Completed NCT00991926 Phase 4
14 Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women Completed NCT00145522 Phase 4
15 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4
16 Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Completed NCT01209403 Phase 4
17 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4
18 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4
19 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4
20 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4
21 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4
22 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4
23 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01014338 Phase 4
24 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4
25 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4
26 Predictive Markers in GHD and TS Children Treated With SAIZEN® Completed NCT00256126 Phase 4
27 Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles Completed NCT02866253 Phase 4
28 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4
29 Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature Completed NCT00458263 Phase 4
30 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4
31 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4
32 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4
33 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
34 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
35 A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy Completed NCT01030094 Phase 4
36 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
37 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4
38 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
39 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
40 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
41 Preterm Infants on Early Solid Foods Recruiting NCT01809548 Phase 4
42 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Recruiting NCT02137538 Phase 4
43 Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis Active, not recruiting NCT02367833 Phase 4
44 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4
45 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Active, not recruiting NCT02311894 Phase 4
46 Assessing the Impact of Contraceptives on Bone Health Using 41Ca Active, not recruiting NCT02367846 Phase 4
47 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Active, not recruiting NCT02357472 Phase 4
48 The Health Influences of Puberty (HIP) Study Active, not recruiting NCT01775813 Phase 4
49 Treatment of Hypoglycemia Following Gastric Bypass Surgery Enrolling by invitation NCT02527993 Phase 4
50 LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD Not yet recruiting NCT02568020 Phase 4

Search NIH Clinical Center for Insulin-Like Growth Factor I

Genetic Tests for Insulin-Like Growth Factor I

Genetic tests related to Insulin-Like Growth Factor I:

id Genetic test Affiliating Genes
1 Insulin-Like Growth Factor 1 Resistance to 29
2 Insulin-Like Growth Factor I, Resistance to 24 IGF1R

Anatomical Context for Insulin-Like Growth Factor I

MalaCards organs/tissues related to Insulin-Like Growth Factor I:

39
Breast, Prostate, Bone, Liver, Smooth Muscle, Pituitary, Endothelial

Publications for Insulin-Like Growth Factor I

Articles related to Insulin-Like Growth Factor I:

(show top 50) (show all 2621)
id Title Authors Year
1
Effect of pre- and postpartum supplementation with lipid-encapsulated conjugated linoleic acid on reproductive performance and the growth hormone-insulin-like growth factor-I axis in multiparous high-producing dairy cows. ( 28456404 )
2017
2
Addition of insulin-like growth factor I to the maturation medium of bovine oocytes subjected to heat shock: effects on the production of reactive oxygen species, mitochondrial activity and oocyte competence. ( 28445838 )
2017
3
Insulin-like growth factor I enhances the developmental competence of yak embryos by modulating aquaporin 3. ( 28512855 )
2017
4
Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. ( 28205047 )
2017
5
A Coordinated Action of Blood-Borne and Brain Insulin-Like Growth Factor I in the Response to Traumatic Brain Injury. ( 28449086 )
2017
6
PEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia. ( 28325900 )
2017
7
To Prime or Not to Prime - Is That Still a Question? A Comment on the US Guidelines on Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. ( 28505613 )
2017
8
Retraction: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells. ( 28394928 )
2017
9
Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias. ( 28467344 )
2017
10
A role for astrocytes in cerebellar deficits in frataxin deficiency: Protection by insulin-like growth factor I. ( 28286293 )
2017
11
Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male. ( 28077934 )
2017
12
Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements. ( 28516748 )
2017
13
Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women. ( 28154269 )
2017
14
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. ( 28478612 )
2017
15
Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. ( 27870006 )
2017
16
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ( 28110155 )
2017
17
Feed restriction and insulin-like growth factor-I (IGF-I) affect the oocyte maturation in matrinxAL Brycon amazonicus. ( 27928979 )
2017
18
Defining human insulin-like growth factor I gene regulation. ( 27406741 )
2016
19
Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer. ( 27737962 )
2016
20
Bioavailable insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women. ( 27749737 )
2016
21
The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. ( 27292418 )
2016
22
Treatment with recombinant human insulin-like growth factor-I improves growth in patients with PAPP-A2 deficiency. ( 27648969 )
2016
23
Regulation of sex steroid production and mRNAs encoding gonadotropin receptors and steroidogenic proteins by gonadotropins, cyclic AMP and insulin-like growth factor-I in ovarian follicles of rainbow trout (Oncorhynchus mykiss) at two stages of vitellogenesis. ( 27387444 )
2016
24
Serum Insulin-like Growth Factor I Quantitation by Mass Spectrometry: Insights for Protein Quantitation with this Technology. ( 28149264 )
2016
25
Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function. ( 27744417 )
2016
26
Low Serum Insulin-Like Growth Factor-I Predicts Cognitive Decline in Alzheimer's Disease. ( 27031487 )
2016
27
Insulin-like growth factor-I serum levels and their biological effects on Leishmania isolates from different clinical forms of American tegumentary leishmaniasis. ( 27286813 )
2016
28
Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. ( 26932768 )
2016
29
Increased diet-induced fatty streak formation in female mice with deficiency of liver-derived insulin-like growth factor-I. ( 26627099 )
2016
30
Astrocyte resilience to oxidative stress induced by insulin-like growth factor I (IGF-I) involves preserved AKT (protein kinase B) activity. ( 27261528 )
2016
31
Reflections on the US Guidelines on Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. ( 27898423 )
2016
32
Rearing Mozambique tilapia in tidally-changing salinities: Effects on growth and the growth hormone/insulin-like growth factor I axis. ( 27032617 )
2016
33
Clinical Evaluation of Insulin like Growth Factor-I and Vascular Endothelial Growth Factor with Alloplastic Bone Graft Material in the Management of Human Two Wall Intra-Osseous Defects. ( 27790578 )
2016
34
c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes. ( 27232975 )
2016
35
The insulin-like growth factor I receptor regulates glucose transport by astrocytes. ( 27462832 )
2016
36
Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. ( 26893016 )
2016
37
A Concerted Action Of Estradiol And Insulin Like Growth Factor I Underlies Sex Differences In Mood Regulation By Exercise. ( 27170462 )
2016
38
Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. ( 26888146 )
2016
39
Astrocyte Resilience to Oxidative Stress Induced by Insulin-like Growth Factor I (IGF-I) Involves Preserved AKT (Protein Kinase B) Activity. ( 26631726 )
2016
40
Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. ( 27349183 )
2016
41
Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. ( 28435630 )
2016
42
Reference values for insulin-like growth factor I (IGF-I) serum concentrations: comparison of six immunoassays. ( 27167056 )
2016
43
Incidence of apoptosis after retinoids and insulin-like growth factor-I (IGF-I) supplementation during goat in vitro embryo production. ( 27587268 )
2016
44
The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. ( 27444280 )
2016
45
Insulin-Like Growth Factor I Receptor (IGF-IR) Ligands and BMI in Squamous Intra-Epithelial Lesion (SIL) of Cervix. ( 27042445 )
2016
46
High-intensity interval training (HIIT) increases insulin-like growth factor-I (IGF-I) in sedentary aging men but not masters' athletes: an observational study. ( 28042739 )
2016
47
Survivin as a Novel Biomarker in the Pathogenesis of Acne Vulgaris and Its Correlation to Insulin-Like Growth Factor-I. ( 27803511 )
2016
48
POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. ( 27529840 )
2016
49
Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? ( 26824335 )
2016
50
Nutritional Status in Short Stature Children is Related to Both Ghrelin and Insulin-like Growth Factor I Concentrations. ( 27557428 )
2016

Variations for Insulin-Like Growth Factor I

UniProtKB/Swiss-Prot genetic disease variations for Insulin-Like Growth Factor I:

66
id Symbol AA change Variation ID SNP ID
1 IGF1R p.Arg138Gln VAR_034891 rs121912426
2 IGF1R p.Lys145Asn VAR_034892 rs121912427
3 IGF1R p.Arg739Gln VAR_034895 rs121912429
4 IGF1R p.Asn359Tyr VAR_076247
5 IGF1R p.Tyr865Cys VAR_076248
6 IGF1R p.Arg1256Ser VAR_076249
7 IGF1R p.Arg1337Cys VAR_076250 rs141802822

ClinVar genetic disease variations for Insulin-Like Growth Factor I:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IGF1 IGF1, EX4-5DEL deletion Pathogenic
2 IGF1 IGF1, MUTATION IN POLYADENYLATION SIGNAL, T-A single nucleotide variant Pathogenic
3 IGF1 NM_001111284.1(IGF1): c.226G> A (p.Val76Met) single nucleotide variant Pathogenic rs121912430 GRCh37 Chromosome 12, 102813415: 102813415
4 IGF1R NM_000875.4(IGF1R): c.413G> A (p.Arg138Gln) single nucleotide variant protective rs121912426 GRCh37 Chromosome 15, 99251109: 99251109
5 IGF1R NM_000875.4(IGF1R): c.435A> C (p.Lys145Asn) single nucleotide variant protective rs121912427 GRCh37 Chromosome 15, 99251131: 99251131
6 IGF1R NM_000875.4(IGF1R): c.265C> T (p.Arg89Ter) single nucleotide variant protective rs121912428 GRCh37 Chromosome 15, 99250961: 99250961
7 IGF1R NM_000875.4(IGF1R): c.2216G> A (p.Arg739Gln) single nucleotide variant protective rs121912429 GRCh37 Chromosome 15, 99465391: 99465391
8 IGF1R NM_000875.4(IGF1R): c.1532G> A (p.Arg511Gln) single nucleotide variant protective rs33958176 GRCh37 Chromosome 15, 99454613: 99454613
9 IGF1 NM_001111283.2(IGF1): c.292C> T (p.Arg98Trp) single nucleotide variant Pathogenic rs587779350 GRCh37 Chromosome 12, 102813397: 102813397
10 IGF1R NM_001291858.1(IGF1R): c.3184-2A> T single nucleotide variant Likely pathogenic rs886042346 GRCh37 Chromosome 15, 99478543: 99478543

Expression for Insulin-Like Growth Factor I

Search GEO for disease gene expression data for Insulin-Like Growth Factor I.

Pathways for Insulin-Like Growth Factor I

Pathways related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 AKT1 AKT2 EGF GH1 IGF1 IGF1R
2
Show member pathways
13.96 AKT1 AKT2 EGF GH1 IGF1 IGF1R
3
Show member pathways
13.9 GH1 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3
4
Show member pathways
13.82 AKT1 AKT2 EGF GH1 IGF1 IGF1R
5
Show member pathways
13.56 AKT1 AKT2 EGF GH1 GHR IGF1
6
Show member pathways
13.47 AKT1 AKT2 EGF GH1 IGF1 IGF1R
7
Show member pathways
13.42 AKT1 AKT2 EGF IGF1 IGF2 ITGA6
8
Show member pathways
13.4 AKT1 EGF GH1 IGF1 IGF1R IGF2
9
Show member pathways
13.38 AKT1 AKT2 EGF GH1 IGF1 IGF1R
10
Show member pathways
13.36 AKT1 EGF GH1 IGF1 IGF1R IGF2
11
Show member pathways
13.32 AKT1 AKT2 EGF GH1 GHR IGF1
12
Show member pathways
13.19 AKT1 AKT2 EGF INS INSR IRS1
13
Show member pathways
13.17 AKT1 EGF GH1 IGF1 IGF1R IGF2
14
Show member pathways
13.15 AKT1 AKT2 EGF GH1 IGF1 IGF1R
15
Show member pathways
13.13 AKT1 AKT2 EGF IGF1 IGF1R INS
16
Show member pathways
13.1 IGF1 IGF1R IGF2 INSR ITGA6 ITGAV
17
Show member pathways
13.02 AKT1 AKT2 EGF IGF1 IGF1R ITGA6
18
Show member pathways
12.93 AKT1 INS INSR IRS1 ITGA6 ITGAV
19
Show member pathways
12.93 AKT1 AKT2 IGF1 IGF1R IGF2 INSR
20
Show member pathways
12.89 AKT1 AKT2 IGF1 IGF1R IGF2
21
Show member pathways
12.86 AKT1 AKT2 INS INSR IRS1
22
Show member pathways
12.86 AKT1 AKT2 EGF IGF1 IGF1R INS
23
Show member pathways
12.84 AKT1 AKT2 EGF INS INSR IRS1
24
Show member pathways
12.83 AKT1 AKT2 EGF GH1 GHR IGF1
25 12.8 AKT1 AKT2 EGF IGF1 IGF1R ITGA6
26
Show member pathways
12.79 AKT1 EGF GH1 IGF1 IGF2
27 12.72 EGF INS ITGA6 ITGAV ITGB3
28
Show member pathways
12.69 AKT1 AKT2 EGF IGF1 IGF1R IRS1
29
Show member pathways
12.66 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
30
Show member pathways
12.65 AKT1 AKT2 IGF1R INS INSR IRS1
31
Show member pathways
12.65 AKT1 AKT2 IGF1 IGF1R INS INSR
32
Show member pathways
12.59 AKT1 AKT2 GH1 INS IRS1
33
Show member pathways
12.57 AKT1 AKT2 IGF1 IGF1R INS INSR
34
Show member pathways
12.55 AKT1 AKT2 IGF1R INSR ITGAV
35
Show member pathways
12.52 AKT1 AKT2 EGF INS INSR
36
Show member pathways
12.5 AKT1 AKT2 EGF IGF1 IGF1R IRS1
37 12.5 AKT1 AKT2 EGF GH1 GHR IGF1
38
Show member pathways
12.49 EGF ITGA6 ITGAV ITGB3
39 12.49 AKT1 AKT2 IGF1R IGFBP1 IGFBP2 IGFBP3
40
Show member pathways
12.47 AKT1 AKT2 ITGAV ITGB3
41
Show member pathways
12.46 AKT1 AKT2 IGF1 IGF1R INS
42
Show member pathways
12.45 AKT1 AKT2 EGF IGF1 IGF1R INSR
43
Show member pathways
12.43 AKT1 IRS1 ITGA6 ITGAV
44 12.42 AKT1 AKT2 IGF1 IGF1R IGF2 ITGAV
45
Show member pathways
12.38 AKT1 AKT2 IGF1 IGF1R IRS1
46
Show member pathways
12.33 AKT1 AKT2 INS INSR IRS1
47
Show member pathways
12.32 AKT1 AKT2 ITGAV ITGB3
48
Show member pathways
12.31 IGF1 ITGA6 ITGAV ITGB3
49
Show member pathways
12.3 AKT1 AKT2 GH1 GHR
50
Show member pathways
12.29 AKT1 AKT2 EGF IGF1 IGF1R

GO Terms for Insulin-Like Growth Factor I

Cellular components related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.89 IGFBP1 IGFBP3 IGFBP4 IGFBP5 INS
2 receptor complex GO:0043235 9.77 EGF GHR IGF1R INSR ITGB3
3 ruffle membrane GO:0032587 9.7 AKT2 ITGAV ITGB3
4 platelet alpha granule lumen GO:0031093 9.69 EGF IGF1 IGF2
5 integrin complex GO:0008305 9.63 ITGA6 ITGAV ITGB3
6 insulin receptor complex GO:0005899 9.48 INSR IRS1
7 growth hormone receptor complex GO:0070195 9.43 GH1 GHR
8 integrin alphav-beta3 complex GO:0034683 9.4 ITGAV ITGB3
9 insulin-like growth factor ternary complex GO:0042567 9.33 IGF1 IGFBP3 IGFBP5
10 insulin-like growth factor binding protein complex GO:0016942 9.13 IGF1 IGFBP3 IGFBP5
11 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.92 IGF1 IGF1R ITGAV ITGB3
12 extracellular region GO:0005576 10.1 EGF GH1 GHR IGF1 IGF2 IGFBP1
13 extracellular space GO:0005615 10 EGF GH1 GHR IGF1 IGF2 IGFBP1

Biological processes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.98 EGF IGF1 IGF2 ITGB3
2 activation of MAPK activity GO:0000187 9.98 EGF GHR IGF1 INSR
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.98 EGF GH1 GHR IGF1 IGF2 INS
4 phosphatidylinositol-mediated signaling GO:0048015 9.97 AKT1 EGF IGF1 IGF1R IRS1
5 glucose homeostasis GO:0042593 9.97 AKT1 IGFBP5 INS INSR IRS1
6 positive regulation of protein kinase B signaling GO:0051897 9.96 IGF2 IGFBP5 INS INSR
7 cellular response to insulin stimulus GO:0032869 9.96 AKT1 AKT2 GHR INSR IRS1
8 regulation of growth GO:0040008 9.93 IGFBP2 IGFBP3 IGFBP4 IGFBP5
9 regulation of cell growth GO:0001558 9.93 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
10 integrin-mediated signaling pathway GO:0007229 9.91 ITGA6 ITGAV ITGB3
11 glucose metabolic process GO:0006006 9.91 AKT1 AKT2 IGF2 IGFBP5 INS
12 positive regulation of MAPK cascade GO:0043410 9.91 IGF1 IGF2 IGFBP3 IGFBP4 INS INSR
13 cellular protein metabolic process GO:0044267 9.91 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3 IGFBP4
14 positive regulation of cell growth GO:0030307 9.9 AKT1 IGFBP1 INS
15 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.9 AKT1 EGF IRS1
16 cellular response to organic cyclic compound GO:0071407 9.9 AKT1 IGFBP5 ITGA6
17 regulation of cell migration GO:0030334 9.9 AKT1 AKT2 ITGB3
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 GH1 IGF1 INS
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 GH1 GHR IGF1
20 positive regulation of DNA replication GO:0045740 9.88 IGF1 IGF1R INS INSR
21 positive regulation of mitotic nuclear division GO:0045840 9.88 EGF IGF1 IGF2 INS INSR
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 AKT1 INS INSR
23 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.86 IGF1 ITGA6 ITGAV
24 glucose transport GO:0015758 9.86 AKT1 GH1 INS
25 positive regulation of activated T cell proliferation GO:0042104 9.85 IGF1 IGF2 IGFBP2
26 ERK1 and ERK2 cascade GO:0070371 9.85 EGF IGF1 ITGAV
27 phosphatidylinositol 3-kinase signaling GO:0014065 9.85 AKT1 IGF1 IGF1R IRS1
28 insulin-like growth factor receptor signaling pathway GO:0048009 9.85 AKT1 GHR IGF1 IGF1R IRS1
29 activation of protein kinase B activity GO:0032148 9.84 IGF1 INS INSR
30 regulation of glucose metabolic process GO:0010906 9.83 IGFBP3 IGFBP4 IGFBP5
31 cell-substrate adhesion GO:0031589 9.82 ITGA6 ITGAV ITGB3
32 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.82 GH1 GHR IGF1
33 cell adhesion mediated by integrin GO:0033627 9.81 ITGA6 ITGAV ITGB3
34 positive regulation of glycolytic process GO:0045821 9.8 IGF1 INS INSR
35 response to growth hormone GO:0060416 9.8 AKT1 GHR IGFBP5
36 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.8 GH1 IGF1 IGFBP3 IGFBP4 IGFBP5
37 positive regulation of glucose import GO:0046326 9.8 AKT1 AKT2 IGF1 INS INSR IRS1
38 positive regulation of insulin receptor signaling pathway GO:0046628 9.79 IGF2 INS IRS1
39 positive regulation of glucose metabolic process GO:0010907 9.77 AKT1 AKT2 IRS1
40 type B pancreatic cell proliferation GO:0044342 9.77 IGFBP3 IGFBP4 IGFBP5
41 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 ITGAV ITGB3
42 striated muscle cell differentiation GO:0051146 9.73 AKT1 IGFBP5
43 positive regulation of lipid biosynthetic process GO:0046889 9.73 AKT1 INS
44 positive regulation of fatty acid beta-oxidation GO:0032000 9.72 AKT2 IRS1
45 negative regulation of lipid storage GO:0010888 9.72 ITGAV ITGB3
46 growth hormone receptor signaling pathway GO:0060396 9.71 GH1 GHR
47 cell-substrate junction assembly GO:0007044 9.71 ITGA6 ITGB3
48 peripheral nervous system myelin maintenance GO:0032287 9.71 AKT1 AKT2
49 positive regulation of respiratory burst GO:0060267 9.71 INS INSR
50 apolipoprotein A-I-mediated signaling pathway GO:0038027 9.7 ITGAV ITGB3

Molecular functions related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.96 IGFBP1 IGFBP2 IGFBP4 IGFBP6 ITGAV
2 growth factor activity GO:0008083 9.84 EGF GH1 IGF1 IGF2
3 hormone activity GO:0005179 9.78 GH1 IGF1 IGF2 INS
4 insulin receptor binding GO:0005158 9.77 IGF1 IGF1R IGF2 INS IRS1
5 growth factor binding GO:0019838 9.73 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
6 insulin-like growth factor receptor binding GO:0005159 9.72 IGF1 IGF2 INS INSR IRS1
7 fibronectin binding GO:0001968 9.71 IGFBP3 IGFBP5 ITGAV ITGB3
8 insulin-like growth factor binding GO:0005520 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
9 insulin-like growth factor I binding GO:0031994 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
10 protein kinase C binding GO:0005080 9.69 AKT1 IRS1 ITGAV
11 phosphatidylinositol 3-kinase binding GO:0043548 9.63 IGF1R INSR IRS1
12 neuregulin binding GO:0038132 9.61 ITGA6 ITGAV ITGB3
13 insulin receptor substrate binding GO:0043560 9.57 IGF1R INSR
14 insulin binding GO:0043559 9.55 IGF1R INSR
15 C-X3-C chemokine binding GO:0019960 9.52 ITGAV ITGB3
16 insulin-like growth factor II binding GO:0031995 9.17 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
17 protein binding GO:0005515 10.45 AKT1 AKT2 EGF GH1 GHR IGF1

Sources for Insulin-Like Growth Factor I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....